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Rates of infection with antibiotic-resistant bacteria have increased precipitously over the
past several decades, with far-reaching healthcare and societal costs. Recent evidence
has established a link between antibiotic resistance genes in human pathogens and
those found in non-pathogenic, commensal, and environmental organisms, prompting
deeper investigation of natural and human-associated reservoirs of antibiotic resistance.
Functional metagenomic selections, in which shotgun-cloned DNA fragments are selected
for their ability to confer survival to an indicator host, have been increasingly applied
to the characterization of many antibiotic resistance reservoirs. These experiments have
demonstrated that antibiotic resistance genes are highly diverse and widely distributed,
many times bearing little to no similarity to known sequences. Through unbiased
selections for survival to antibiotic exposure, functional metagenomics can improve
annotations by reducing the discovery of false-positive resistance and by allowing for the
identification of previously unrecognizable resistance genes. In this review, we summarize
the novel resistance functions uncovered using functional metagenomic investigations
of natural and human-impacted resistance reservoirs. Examples of novel antibiotic
resistance genes include those highly divergent from known sequences, those for which
sequence is entirely unable to predict resistance function, bifunctional resistance genes,
and those with unconventional, atypical resistance mechanisms. Overcoming antibiotic
resistance in the clinic will require a better understanding of existing resistance reservoirs
and the dissemination networks that govern horizontal gene exchange, informing best
practices to limit the spread of resistance-conferring genes to human pathogens.
Keywords: functional metagenomics, antibiotic resistance, bifunctional resistance gene, environmental resistance,
resistance reservoir, transferable resistance
OVERVIEW
It is estimated that infection with antibiotic-resistant pathogens
incurs over $25 billion in societal and healthcare costs annu-
ally in the United States (CDC, 2011). More than 70% of
hospital-acquired bacterial infections are currently resistant to
at least one of the major antibiotics used as standard treat-
ment (Stone, 2009), and patient deaths as a result of hospital-
acquired infections have increased by over 675% during the
past 20 years (NIAID, 2012). As the incidence and spectrum
of antibiotic resistance increases (Arias and Murray, 2009),
antibiotic development has slowed to a trickle (Spellberg et al.,
2008), further hindering the effectiveness of antibiotics to treat
infectious disease. The majority of acquired antibiotic resis-
tance genes in bacterial pathogens are obtained via horizon-
tal gene transfer (HGT) (Ochman et al., 2000), likely with
environmental origins (Benveniste and Davies, 1973; Wright,
2010; D’Costa et al., 2011). Accordingly, an increasing impe-
tus has been placed on cataloging antibiotic resistance reservoirs
(Allen et al., 2009b, 2010), determining how resistance genes
are most readily transferred to the clinic (Marshall and Levy,
2011; Smillie et al., 2011), and identifying resistance mechanisms
heretofore unseen in clinical settings (Jeon et al., 2011; Tao et al.,
2012).
TRADITIONAL MECHANISMS OF ANTIBIOTIC RESISTANCE
An antibiotic-resistant phenotype can be either an acquired trait
or intrinsic to the bacterium in question. In the case of intrinsic
resistance, antibiotic therapy is rendered ineffective due to a pre-
existing physiological trait of the species, such as reduced acces-
sibility to or absence of a drug target (Alekshun and Levy, 2007;
Martinez, 2008; Davies and Davies, 2010; Dantas and Sommer,
2012). Examples of intrinsic antibiotic resistance include van-
comycin tolerance in Gram-negative bacteria (the outer cell
membrane reduces access to the peptidoglycan target) (Arthur
and Courvalin, 1993) and biofilm formation in numerous organ-
isms (perhaps providing resistance via reduced drug penetra-
tion and/or altered microenvironments) (Stewart and Costerton,
2001). Conversely, acquired antibiotic resistance stems from the
expression of a specific resistance gene and is commonly the result
of de novo mutation or the acquisition of resistance-conferring
genes on mobile genetic elements (e.g., plasmids, transposons,
integrons) (Walsh, 2003). The antibiotic resistance genes present
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in a microbial community that are capable of transfer to a new
host are collectively referred to as the “transferable resistome.”
Intrinsic resistance is, by definition, limited to the context of
the parent organism, whereas acquired resistance represents a
more flexible phenotype, and its prevalence is more immedi-
ately responsive to selection pressure (Martinez, 2008). As nearly
all infectious bacteria were antibiotic-susceptible prior to the
introduction of antibiotic therapy (Houndt and Ochman, 2000;
Davies and Davies, 2010), the exceeding majority of resistance in
human pathogens is acquired, either through mutation or HGT
(Alekshun and Levy, 2007). This resistance represents a diversity
of biochemical mechanisms that break down into three general
categories (Walsh, 2000, 2003): (1) inactivation of the antibiotic,
(2) reducing intracellular antibiotic concentration through efflux
or permeability barriers, and (3) altering the cellular target of the
antibiotic, reducing their association.
Perhaps the most intuitive of resistance mechanisms, antibi-
otic inactivation, is sub-categorized into two groups: enzymes
that inactivate drugs via degradation (e.g., the β-lactamases) vs.
those that function via chemical modification. The β-lactamases
are characterized by their ability to cleave the four-membered
ring present in all β-lactam antibiotics and are some of the
best-studied and widely-distributed antibiotic resistance genes
(for review, see Jacoby and Munoz-Price, 2005). These enzymes
confer high-level antibiotic resistance and are found associ-
ated with mobile DNA elements and integrated into bacte-
rial chromosomes. β-lactamases function via either a serine
active site or metal cation cofactor (Jacoby and Munoz-Price,
2005) and can be found across bacterial phyla. Antibiotic-
modifying enzymes are also phylogenetically widespread, as well
as mechanistically diverse. These enzymes can confer tolerance
toward numerous drugs, including the aminoglycoside (Davies
and Wright, 1997), tetracycline (Yang et al., 2004), amphenicol
(Schwarz et al., 2004), and macrolide-lincosamide-streptogramin
(Weisblum, 1998) antibiotics, typically functioning via covalent
modification of the drug with some functional moiety (e.g.,
acetyl, phosphoryl, nucleotidyl, glycosyl, and hydroxyl groups)
(Alekshun and Levy, 2007).
The intracellular concentration of any given antibiotic can be
reduced by either efflux mechanisms to remove the drug from the
cytosol or permeability barriers that limit the drug’s uptake.Many
antibiotics have poor activity against Gram-negative pathogens
due to efflux systems (Levy, 1992), most notably the RND super-
family transporters (Li and Nikaido, 2004, 2009). Other major
families of efflux systems include the MFS, SMR, and ABC super-
family transporters, which are present in both Gram-negative and
-positive organisms (Li and Nikaido, 2004, 2009). Although com-
monly chromosomal, many efflux systems are found on plasmids
and other mobile elements and can confer drug-specific, class-
specific, ormultidrug resistance (Poole, 2005). Some permeability
barriers, such as the Gram-negative outer membrane (Arthur and
Courvalin, 1993), represent intrinsic antibiotic resistance, while
in other instances, permeability barriers are acquired. Examples
include multidrug-resistance via the altered expression of Gram-
negative porin proteins (e.g., OmpF in Escherichia coli and OprD
in Pseudomonas) (Delcour, 2009) and glycopeptide resistance due
to thickened Gram-positive cell walls (Cui et al., 2006).
Antibiotic resistance via cellular target modification often
occurs via chromosomal mutation and represents a com-
mon means by which the fluoroquinolone, sulfonamide, and
trimethroprim antibiotics, among others, are tolerated (Alekshun
and Levy, 2007). In the case of the fluoroquinolones, muta-
tions to a variety of residues within the quinolone-resistance-
determining-region (QRDR) of the DNA gyrase GyrA or topoi-
somerase IV ParC/GrlA prevent the interaction of the synthetic
antibiotic with its target, facilitating resistance (Hooper, 1999).
Importantly, resistance to fluoroquinolones via mutation is typ-
ically recessive, suppressing the acquisition of a resistant phe-
notype in the presence of wild-type GyrA or ParC/GrlA and
thus preventing widespread horizontal dissemination of resis-
tant gene variants (Wolfson and Hooper, 1989; Soussy et al.,
1993). However, a plasmid-borne GyrA protection protein, Qnr,
has been discovered that confers low-level fluoroquinolone resis-
tance (Tran and Jacoby, 2002) and can potentiate the incidence
of QRDR mutations, which combined provide high levels of
resistance (Jacoby, 2005). Both the sulfonamides and trimethro-
prim competitively inhibit enzymes within the folate biosyn-
thesis pathway: mutations to the dihydropteroate synthase and
dihydrofolate reductase (DHFR) enzymes can reduce affinity
for sulfonamides and trimethroprim, respectively, and provide
tolerance to the antibiotics (Huovinen et al., 1995). In addi-
tion to arising de novo, both sulfonamide- and trimethroprim-
resistant enzymes are present on mobile DNA elements, provid-
ing resistance to numerous bacteria via HGT (Alekshun and Levy,
2007). Other highly mobile mechanisms of target-modification
include vancomycin resistance via the modification of peptido-
glycan precursors (Bugg et al., 1991), aminoglycoside resistance
via methylation of the 16S rRNA subunit (Galimand et al.,
2003), and macrolide resistance from 23S rRNA methylases
(Zhanel et al., 2001).
RESERVOIRS OF TRANSFERABLE ANTIBIOTIC RESISTANCE
Research on antibiotic resistance over the past 70 years has
focused on traditionally pathogenic bacteria isolated in a clinical
setting and the role of antibiotic resistance genes already present
in those species (Sommer et al., 2009; Davies and Davies, 2010).
The resistance phenotype, however, is an ancient function of envi-
ronmental bacteria (D’Costa et al., 2011), despite being largely
absent from human pathogens prior to the antibiotic age (Hughes
and Datta, 1983; Houndt and Ochman, 2000), with estimates
that β-lactamases have existed for over 2 billion years (Hall and
Barlow, 2004; Hall et al., 2004). Moreover, diverse mechanisms
of antibiotic resistance have been discovered in nearly all envi-
ronments (D’Costa et al., 2006; Allen et al., 2010; Davies and
Davies, 2010; Wright, 2010); seemingly each new metagenomic
study uncovers numerous examples of resistance genes previously
unreported in public databases (Allen et al., 2009b; Sommer et al.,
2009; Donato et al., 2010; Forsberg et al., 2012). In short, the
diversity and abundance of antibiotic resistance in commensal
microbiota and environmental settings dwarfs that which is seen
in the context of human pathogens.
Importantly, environmental antibiotic resistance is not only
widespread, but also represents the likely origins of the resistance
seen in human pathogens. It has been known for 40 years that
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environmental bacteria share the same resistance mechanisms
as those seen in pathogens (Benveniste and Davies, 1973), with
documented examples of environmental resistance genes mov-
ing from natural settings into human pathogens (Poirel et al.,
2002, 2005). It is becoming increasingly evident that human
pathogens and environmental organisms share antibiotic resis-
tance genes; a recent study described seven resistance genes
from non-pathogenic soil organisms, conferring tolerance to five
antibiotic classes, with perfect identity to genes from phyloge-
netically and geographically diverse pathogens (Forsberg et al.,
2012). Given the staggering diversity of environmental resistance,
high adaptability of bacteria, and strong selection pressure for
antibiotic resistance, the question of antibiotic resistance is “not a
matter of if but only a matter of when” (Walsh, 2000).
To understand when novel resistance will appear in human
pathogens and perhaps diminish its impact, one must under-
stand how new resistance genes are most frequently acquired by
pathogenic bacteria. Since the answer is, most commonly, via
HGT (Hughes and Datta, 1983; Ochman et al., 2000; Alekshun
and Levy, 2007), understanding the complement of resistance
genes most likely to be transferred to pathogens is crucial to
predicting resistance acquisition. Although cataloging the reper-
toire of resistance genes on Earth remains a prohibitively large
undertaking, techniques for interrogating the resistance proper-
ties of complexmicrobial communities exist and are being applied
toward the identification of diverse and novel resistance from
numerous settings. Importantly, these studies are focused not
only on environmental locales, but also on the resistomes associ-
ated with human and animal microbiota (Shoemaker et al., 2001;
Sommer et al., 2010b; Sommer and Dantas, 2011). Although
antibiotic resistance may have its origins in the environment
(Benveniste and Davies, 1973; Wright, 2010; D’Costa et al., 2011),
the commensal resistome shares many resistance genes with both
pathogens (Sommer et al., 2010b) and environmental organ-
isms (Forsberg et al., 2012) and represents a likely route through
which these populations exchange resistance genes (Smillie et al.,
2011; Sommer and Dantas, 2011). Focused efforts to understand
how pathogens acquire antibiotic resistance will require a greater
appreciation for the diversity of resistance genes and in which
environments and under what conditions these resistance genes
are most accessible to human pathogens.
INTERROGATING ANTIBIOTIC RESISTANCE PROPERTIES IN
COMPLEX MICROBIAL COMMUNITIES
Traditionally, either culture-based (D’Costa et al., 2006) or PCR-
based approaches (Perez-Perez andHanson, 2002) have been used
to study antibiotic resistance properties from microbial com-
munities. While both techniques have led to major discoveries
(Galan et al., 2013), both have inherent limitations that have con-
tributed to an under-sampling of resistance genes from diverse
microbial habitats. The majority of bacteria remain recalcitrant
to culturing (Daniel, 2005) and are therefore not interrogated
when culture-dependent techniques are employed. Additionally,
linking a resistance phenotype to a causal genotype is a time-
consuming process, often necessitating experimental scope to
be limited to a small number of organisms, rather than whole
communities. PCR screens are an effective means to identify or
quantify resistance genes of known sequence, circumventing the
need for culture (Knapp et al., 2010), but are only able to detect
previously described genes and often require expression cloning
and subsequent experimentation to verify function. In addition,
annotation of antibiotic resistance genes in shotgun-sequenced
microbial communities has proven challenging, as homology-
based functional gene comparisons often fail due to low sequence
similarity to previously discovered resistance genes, and in silico
analyses are unable to confirm resistance function.
In contrast with standard techniques, functional metagenomics
is a culture- and sequence-independent means of identifying
transferrable antibiotic resistance in complex metagenomes. This
method (Figure 1) involves shotgun-cloning total community
DNA into an expression vector and transforming the library into
an indicator host (commonly the model organism E. coli). The
resulting transformants are then selected for the desired function
(e.g., antibiotic resistance), andmetagenomic DNA fragments are
sequenced and annotated to identify causal survival-conferring
genes (Allen et al., 2009b; Sommer et al., 2009). Functional
metagenomics offers three classical advantages for the unbiased
interrogation of complex resistomes (Daniel, 2005; Sommer and
Dantas, 2011): (1) no need to culture organisms, (2) no required
knowledge of resistance gene sequence, and (3) direct association
between a genotype and a demonstrated resistance phenotype.
Additionally, functional metagenomic selections specifically iden-
tify those genes within a metagenome capable of conferring
antibiotic tolerance to the indicator host when expressed exoge-
nously (i.e., they distinguish transferrable resistance from intrin-
sic resistance) (Dantas and Sommer, 2012). Recent improvements
to the throughput of functional metagenomics (Forsberg et al.,
2012) unlock the potential for the experiments of scale needed
identify the specific sequences, and environments, most read-
ily able to confer resistance to human pathogens, frequently
represented by the opportunistic pathogen E. coli.
NOVEL RESISTANCE MECHANISMS UNCOVERED BY
FUNCTIONAL METAGENOMIC SELECTIONS
The following sections review novel resistance mechanisms and
genes uncovered by functional metagenomic selections; these
studies are summarized in Table 1.
GENES HIGHLY DIVERGENT FROM KNOWN RESISTANCE GENES
PCR-based screens for known resistance genes are able to detect
novel variants with minor sequence differences, but due to the
requirement for conserved primer binding sites, they are often
unable to detect genes that have diverged significantly from
the canonical example. In comparison, functional metagenomic
selections for antibiotic resistance frequently identify genes that
are less than 65% identical at the amino acid level to known resis-
tance genes. In this way, functional metagenomics expands our
knowledge of what sequence variants are tolerated in a resistance
gene while preserving the resistance mechanism, as well as what
mutations lead to expanded specificity profiles.
β-lactamases are one of the largest and best studied classes
of resistance determinants, and yet, novel β-lactamases are reg-
ularly uncovered with sequence-independent techniques (Allen
et al., 2009b; Sommer et al., 2009; Donato et al., 2010; Cheng
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FIGURE 1 | Overview of functional metagenomic selections. Total
metagenomic DNA is extracted from a microbial community sample,
sheared, and ligated into an expression vector (Step 1) and is
subsequently transformed into a suitable library host (Step 2) to create a
metagenomic library. The library is then plated on media containing
antibiotics inhibitory to the wild-type host (Step 3) to select for
metagenomic fragments conferring antibiotic resistance. Metagenomic
fragments present in colonies growing on antibiotic selection media are
then PCR-amplified (Step 4) and sequenced using either traditional Sanger
sequencing or next-generation sequencing methods (Step 5). Finally, reads
are assembled and annotated in order to identify the causative antibiotic
resistance genes (Step 6).
et al., 2012; Forsberg et al., 2012). In the first functional metage-
nomic selection for antibiotic resistance in the human gut micro-
biome, Sommer et al. identified ten novel β-lactamase families
whose eleven members were only 35–61% identical to known
genes (Sommer et al., 2009). Based on phylogenetic analysis
with PhyloPythia, (McHardy et al., 2007) these genes originated
primarily from the Firmicutes and Bacteroidetes phyla, which
comprise the majority of the human gutmicrobiota but have been
undersampled because they are less readily culturable in aero-
bic environments than Proteobacteria. Functional selection for
β-lactam resistance in metagenomic libraries constructed from
remote Alaskan soil revealed 13 novel β-lactamases of all four
Ambler classes that were≤67% identical to any known, function-
ally characterized gene (Allen et al., 2009b). In the case of the class
B β-lactamases, several genes appear to be more closely related to
the ancestral gene of that class than to clinically isolated genes,
providing context for the evolution of clinical isolates. The study
also confirmed that overall sequence similarity does not necessar-
ily confer similar drug susceptibility profiles, supporting discov-
ery techniques that confirm the function of identified genes.
Functional metagenomic selections also enable the detection
of highly diverse classes of resistance genes, defined by sub-
strate specificity more than shared sequence identity. For instance,
aminoglycoside 6′-N-acetyltransferases [AAC(6′)s] are difficult
to identify via PCR because of their high sequence diversity
(Riesenfeld et al., 2004). Sommer et al. identified six AAC(6′)s
with less than 48% amino acid identity to known genes and a
methyltransferase conferring resistance to sisomycin with only
26.3% shared identity. Riesenfeld et al. and other studies have
identified many aminoglycoside resistance genes less than 70%
identical to previously reported sequences (Riesenfeld et al., 2004;
Donato et al., 2010; Torres-Cortes et al., 2011; Cheng et al.,
2012; McGarvey et al., 2012). Similarly, two novel bleomycin
resistance genes were isolated from an activated sludge metage-
nomic library (Mori et al., 2008). Bleomycin resistance proteins
act primarily by sequestering the antibiotic through electro-
static interactions, so their sequences tolerate an extreme amount
of divergence while still maintaining the resistance function.
Nevertheless, the study confirmed that all known bleomycin resis-
tance proteins contain a proline near the N-terminus and have an
acidic pI of<5, improving computational annotation of this class.
Finally, McGarvey et al. identified an ADP-ribosyltransferase that
was much longer any previously characterized using functional
metagenomic selections (McGarvey et al., 2012). This full-length
gene may not have been identified by PCR-based screens, but
its discovery, enabled by functional metagenomics, expands our
knowledge of the sequence diversity tolerated within this resis-
tance class.
RESISTANCE GENES THAT WOULD NOT HAVE BEEN PREDICTED
BY SEQUENCE
Amajor limitation of sequence-based metagenomics is its restric-
tion to antibiotic resistance genes that are recognizable as
members of a previously characterized class. BLAST, the most
Frontiers in Microbiology | Antimicrobials, Resistance and Chemotherapy June 2013 | Volume 4 | Article 145 | 4
Pehrsson et al. Functional metagenomics uncovers novel resistance
Table 1 | Functional metagenomic investigations of antibiotic resistance reservoirs.
Resistance reservoir Date Novel resistance function identified Total DNA queried* References
FUNCTIONAL METAGENOMIC INVESTIGATIONS OF ENVIRONMENTAL RESERVOIRS
Soil (remnant oak savannah) 2004 First use of functional metagenomic selections to
investigate environmental antibiotic resistance;
Nine novel aminoglycoside-resistance genes
5.4GB Riesenfeld et al., 2004
Activated sludge 2008 Two novel bleomycin-resistance genes 3.2GB Mori et al., 2008
Remote Alaskan soil 2009 13 novel β-lactamases; First discovery of
bifunctional β-lactamase
12.4GB Allen et al., 2009b
Gypsy moth larvae midgut
isolates
2009 ramA (AraC transcriptional regulator) 0.3GB Allen et al., 2009a
Remote Alaskan soil 2010 pexA (novel chloramphenicol transporter) 13.2GB Lang et al., 2010
Activated sludge 2010 Six novel chloramphenicol-modifying resistance
genes; Novel aminoglycoside-resistance gene
1.9GB Parsley et al., 2010
Soil (apple orchard) 2010 Nine novel β-lactamases; Three novel
aminoglycoside-resistance genes; A novel
tetracycline efflux pump
13.4GB Donato et al., 2010
Alluvial soil 2011 Est136, chloramphenicol acetate esterase 1.6GB Tao, 2011; Tao et al., 2012
Soil (agricultural, nature
reserve)
2011 Tm8-3 (novel dihydrofolate reductase) 3.6GB Torres-Cortes et al., 2011
Wetland soil 2011 EstU1, family VIII carboxylesterase 0.3GB Kim et al., 2008; Jeon et al., 2011
Gull gut microbiome 2011 31 β-lactam resistance genes of undetermined
mechanism
20.5GB Martiny et al., 2011
Urban soil 2012 Novel MFS and ABC transporters; Five novel
aminoglycoside-resistance genes;
ADP-ribosyltransferase longer than any previously
discovered
2.8GB McGarvey et al., 2012
Multidrug-resistant soil
isolates
2012 Novel β-lactamases; D-cycloserine efflux pump 2.6GB Forsberg et al., 2012
FUNCTIONAL METAGENOMIC INVESTIGATIONS OF HUMAN-ASSOCIATED RESERVOIRS
Human oral microbiome 2003 Tetracycline-inactivating protein tet(37) 0.4–1.4MB Diaz-Torres et al., 2003
Human oral microbiome 2006 Tetracycline-resistance genes of undetermined
mechanism
27.8MB Diaz-Torres et al., 2006
Human gut and oral
microbiome
2009 10 new β-lactamase classes; Seven novel
aminoglycoside-resistance genes
9.3GB Sommer et al., 2009
Pig gut microbiome 2009 Tetracycline-resistance genes galE1 and galE2 of
undetermined mechanism
0.1GB Kazimierczak et al., 2009
Human gut microbiome 2012 Confirmed bifunctional aminoglycoside-resistance
gene; Novel β-lactamase; Novel
aminoglycoside-resistance gene
12.5GB Cheng et al., 2012
*For comparison, the genome size of E. coli K-12 substrain MG1655 is 4.64MB.
commonly used annotation tool, requires a threshold of shared
sequence identity for a gene to be considered a member of an
established gene class. Therefore, by definition, this method lim-
its the ability to identify novel resistance genes. In addition, while
profile hiddenMarkovmodel (HMM)-based annotation provides
a sensitive, statistically sound analysis method capable of identify-
ing remote homologs, these models still rely on underlying multi-
ple sequences alignments of previously characterized proteins. In
addition, current profile HMM databases provide high-level clas-
sification of antibiotic resistance genes (e.g., “Beta-Lactamase,”
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rather than “TEM Beta-Lactamase”), providing little functional
information about the gene and its potential resistance profile.
Therefore, while these techniques have the potential to identify
genes that have low sequence identity to known resistance genes,
in the absence of additional functional confirmation, they can-
not identify novel resistance mechanisms or verify that sequence
variants are functional.
Functional metagenomics identifies resistance-conferring ele-
ments without prior knowledge of the sequence, circumventing
this limitation. For instance, in a selection for tetracycline resis-
tance encoded by the human oral metagenome, Diaz-Torres
et al. discovered a novel tetracycline resistance gene, tet(37)
(Diaz-Torres et al., 2003). In vitro analysis indicated that tet(37)
inactivates tetracycline, making it one of only three tetracycline
resistance proteins to utilize this mechanism (Thaker et al., 2010).
tet(37) resembles flavoproteins, oxidoreductases, and NAD(P)-
requiring enzymes in sequence and conserved motifs, but has no
identity to tet(X), the first tetracycline-inactivating gene identi-
fied. It is therefore unlikely that computational annotation would
have identified it as a resistance gene (Diaz-Torres et al., 2003).
Similarly, a study of soil microbiota identified a dihydrofolate-
reducing gene, Tm8-3, that resembles 3-oxoacyl-(acyl-carrier-
protein) reductases but not dhfr, the target of trimethoprim
(Torres-Cortes et al., 2011). A screen of an activated sludge
metagenome also identified six resistance genes that appear
to inactivate chloramphenicol through enzymatic modification,
but which share no significant identity with known chloram-
phenicol acetyltransferases (Parsley et al., 2010). Although these
genes may become important for clinical resistance in the
future, their existence would likely have been overlooked without
high-throughput functional selections independent of previous
sequence knowledge.
Drug efflux is a widespread resistance mechanism common
to many antibiotic classes, but individual transporters identified
through computational annotation methods cannot be assigned
antibiotic efflux properties without functional validation. Small
changes in protein structure can change the drug specificity
profile of an efflux pump and confer or eliminate resistance.
Therefore, functional metagenomic selections are an attractive
alternative for high-throughput characterization of transporters
with tentative resistance annotations (Torres-Cortes et al., 2011).
For instance, in their study of soil isolate metagenomes, Forsberg
et al. identified a novel gene with only low identity to a
drug/metabolite transporter. Were it not for functional selection
of D-cycloserine resistance, this putative transporter would never
have been identified as an antibiotic resistance gene (Forsberg
et al., 2012). McGarvey et al. identified five novel MFS trans-
porters and two ABC transporters from an urban soil that con-
ferred resistance to tetracycline, chloramphenicol, or trimetho-
prim (McGarvey et al., 2012). Lang et al. successfully identified
pexA, a novel amphenicol MFS transporter, despite its low iden-
tity (33%) to other drug resistance transporters, including any
known chloramphenicol exporters (Lang et al., 2010).
BIFUNCTIONAL ENZYMES
Broad-spectrum resistance as a result of bifunctional resistance
genes, the fusion of two complementary enzymatic functions into
a single gene, is recognized as an increasing occurrence in many
pathogens (Kim et al., 2006; Perez et al., 2007; Chandrakanth
et al., 2008). Functional metagenomics provides an opportu-
nity to identify fusion genes that are functionally active against
multiple classes of antibiotic agents from natural resistance reser-
voirs and commensal organisms, and which have the potential to
appear in clinically relevant bacteria.
Recently, functional metagenomic selections of a remote
Alaskan soil revealed a novel bifunctional β-lactamase (Allen
et al., 2009b). The 609-amino-acid protein is nearly double
the length of a typical β-lactamase and is a natural fusion of
genes for two different β-lactamase subclasses. The C-terminal
domain (356 residues) aligns with class C β-lactamases, while
the N-terminal domain (253 residues) aligns with class D
β-lactamases, each contributing to the resistance profile of the
full-length gene. The class C homologue confers resistance to
cephalexin, while the class D homologue is responsible for resis-
tance to amoxicillin, ampicillin, and carbenicillin. The bifunc-
tional fusion gene therefore expands the resistance profile of the
full-length gene beyond what either domain is responsible for
alone (Allen et al., 2009b).
While this was the first bifunctional β-lactamase to be dis-
covered, bifunctional resistance has been documented in the
past, particularly against the aminoglycoside antibiotics (Daigle
et al., 1999; Centrón and Roy, 2002; Dubois et al., 2002;
Mendes et al., 2004; Robicsek et al., 2006). The most common
mechanism of aminoglycoside resistance is deactivation of the
molecule through modification by cytoplasmic enzymes: amino-
glycoside acetyltransferases (AACs), aminoglycoside phospho-
transferases (APHs), or aminoglycoside nucleotidyltransferases
(ANTs). Four bifunctional enzymes, combining two complemen-
tary aminoglycoside-modifying enzymes as separate domains
into a single open reading frame, significantly broadening the
resistance profile, are known. Ferretti et al. reported the first
bifunctional enzyme, AAC(6′)/APH(2′′), demonstrating that it is
capable of both acetylation (ACC activity found in N-terminal
domain) and phosphorylation (APH activity found in C-terminal
domain) of aminoglycosides (Ferretti et al., 1986). This bifunc-
tional enzyme was also discovered in a functional metagenomics
study of the human gut microbiota (Cheng et al., 2012). The
ability to doubly modify aminoglycosides enables this enzyme
to confer resistance to nearly all clinically relevant aminoglyco-
sides except streptomycin and spectinomycin (Daigle et al., 1999).
Similarly, the bifunctional resistance enzymes characterized as
an AAC(3)-Ib/AAC(6′)-Ib′ (Dubois et al., 2002), an ANT(3′′)-
Ii/AAC(6′)-IId (Centrón and Roy, 2002), and an AAC(6′)-
30/AAC(6′)-Ib′ (Mendes et al., 2004) all exhibit an expanded
resistance profile by combining two different aminoglycoside-
modifying enzymes into a single gene.
AAC(6′)-Ib-cr is the only bifunctional resistance enzyme iden-
tified capable of conferring resistance to two different struc-
tural classes of antibiotics, aminoglycosides and fluoroquinolones
(Vetting et al., 2008). A variant of a common aminoglycoside
acetyltransferase AAC(6′)-Ib, AAC(6′)-Ib-cr is also capable of
N-acetylation of fluoroquinolones. Only two codon changes in
the original enzyme are responsible for the fluoroquinolone-
resistance phenotype (Vetting et al., 2008).
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The merger of two genes with complementary enzymatic
activities represents a novel mechanism for overcoming the
increasing challenge by antibiotics, resulting in extremely broad
resistance to entire antibiotic structural classes. It is likely that
more examples of bifunctional resistance exist in the envi-
ronment, and functional metagenomics provides a powerful
technique for the discovery of functionally active bifunctional
enzymes that may have great clinical implications.
UNUSUAL MECHANISMS OF RESISTANCE
Functional metagenomic selections have the potential to identify
another important class of resistance genes, those that have a pri-
mary role in the cell other than antibiotic resistance. This includes
housekeeping genes whose overexpression provides resistance,
general stress response transcription factors, and enzymes with
promiscuous activity.
Selections for trimethoprim resistance, for example, frequently
identify genes encoding DHFR, the cellular target of trimetho-
prim (Torres-Cortes et al., 2011; McGarvey et al., 2012). Cloning
a dhfr homolog into a high copy-number plasmid results in over-
expression of DHFR, which sequesters the antibiotic (Flensburg
and Skold, 1987). McGarvey et al. identified 19 highly diver-
gent DHFRs from a soil metagenome. The proteins shared only
7–44% amino acid identity in pairwise alignments, but a sub-
set selected for further investigation conferred similar levels
of trimethoprim resistance on the host when cloned into the
same position of a high-copy number vector (McGarvey et al.,
2012). Although clinical isolates of E. coli that massively over-
produce DHFR as a result of promoter mutations and intrin-
sically resistant dhfr homologs have been identified (Flensburg
and Skold, 1987), in most instances, resistance conferred by
overexpression of a heterologous gene is likely independent of
its ability to replace the host homolog. Rather, the introduced
gene may sequester enough of the antibiotic to allow the native
homolog to continue functioning. Selections for D-cycloserine
resistance that identify D-alanine-D-alanine ligase, the target of
the antibiotic, likely fall under the same class (Cheng et al., 2012).
Creating and screening libraries in low-copy number vectors
is essential in these instances to identify genes that are natu-
rally resistant to the antibiotic, rather than simply selecting for
overexpression.
In contrast, antibiotic resistance conferred by transcriptional
regulators represents the successful interaction of a heterologous
gene with existing host cellular pathways. The AraC transcrip-
tional stress response regulatorsmarA, soxS, and rob share a highly
overlapping regulon andmediate low-level antibiotic resistance in
E. coli and its close relative E. fergusonii (Alekshun and Levy, 1997;
Martin and Rosner, 2002). As might be expected, these genes
are often identified in functional metagenomic selections against
chloramphenicol, tetracyclines, and other antibiotics when E. coli
is the indicator host. A homolog of the AraC transcriptional reg-
ulator ramA, from Enterobacter sp., was also identified from a
gypsy moth larvae gut isolate metagenomic library as conferring
resistance to E. coli against multiple antibiotics of different classes
when overexpressed (Allen et al., 2009a). These results provide
valuable information about the ability of horizontally acquired
genes from closely related phyla to incorporate into a cell at the
regulatory level, a mechanism of antibiotic resistance that has
been previously under-considered.
Certain genes identified by functional metagenomic selections
are surprising in that they more closely resemble protein families
that perform unrelated functions in the cell than previously iden-
tified resistance genes. They may represent instances of expanded
substrate specificity, where mutation to a gene with an unrelated
function confers resistance. By first screening a soil metagenomic
library for esterase activity, Jeon et al. identified a family VIII
carboxylesterase that hydrolyzes both esters and the amide bond
of β-lactams, apparently utilizing the same catalytic site residues
for both reactions (Jeon et al., 2011). The protein changes that
enable it to also hydrolyze β-lactams are currently unidentified. A
novel chloramphenicol acetate esterase, EstDL136, isolated from a
soil metagenome, hydrolyzes the amide linkage of both chloram-
phenicol and its synthetic derivative florfenicol (Tao, 2011; Tao
et al., 2012). Many of the surrounding genes in the metagenomic
fragment are most closely related to Sphingomonadaceae, which
are frequently considered for bioremediation for their ability to
degrade many compounds (Stolz, 2009). EstDL136 may have
originally evolved to detoxify another compound, later expanding
its substrate specificity to chloramphenicol.
FUTURE DIRECTIONS AND CHALLENGES
Functional metagenomic selections have proven to be an excel-
lent technique for the discovery of novel antibiotic resistance
mechanisms and genes encoded by varied environmental and
human-associated microbial communities. As library sizes con-
tinue to increase, diverse indicator hosts are established, and
techniques for improved functional selection and mechanistic
determination are developed, functional metagenomics will only
become better powered to explore the transferable resistome of
complex microbial communities.
All of the metagenomic libraries discussed above were con-
structed in E. coli. The commercial availability of compe-
tent E. coli with extremely high transformation efficiencies has
made this organism the preferred host for library construc-
tion, and these studies show that E. coli permits the heterol-
ogous expression of genes from many phyla. However, there
are many clinically important classes of antibiotics that are
intrinsically inactive against this Gram-negative species (e.g., gly-
copeptides, macrolides, oxazolidinones), prohibiting functional
metagenomic selections in this host from identifying antibiotic
resistance genes active against these classes. Development of a
Gram-positive indicator host will represent a major step forward
for the field (Riesenfeld et al., 2004; Sommer et al., 2009). This
host must also exhibit a high transformation efficiency to enable
the creation of metagenomic libraries large enough to permit the
discovery of novel resistance genes and should lack restriction-
modification systems or other host defenses that would prevent
the expression of foreign DNA. E. coli mutants that mimic Gram-
positive species through the alteration of cell membrane and wall
structure are another possible alternative (Tamae et al., 2008).
The taxa from which antibiotic resistance genes can be
expressed in E. coli are also limited by the ability of the host
to recognize gene promoters and ribosome binding sites and
translate them into functional proteins. Engineering E. coli to
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produce tRNA that recognize rare codons and alternative sigma
factors will expand the range of taxa interrogated (Riesenfeld
et al., 2004; Sommer et al., 2009, 2010a).
Finally, genes of unknown function should be further inves-
tigated to determine their mechanisms of resistance. Functional
metagenomic selections that uncover a multitude of confirmed
resistance genes in a high-throughput manner often require com-
plementary biochemical experimentation to understand novel
mechanisms of antibiotic resistance. Many metagenomic func-
tional selections have identified resistance-conferring inserts
whose mechanisms remain obscure because they cannot be deter-
mined based on sequence alone (Riesenfeld et al., 2004; Diaz-
Torres et al., 2006; Kazimierczak et al., 2009; Martiny et al., 2011;
McGarvey et al., 2012). These genes are excellent candidates for
future functional characterization.
ALTERNATIVE STRATEGIES TO COMBAT ANTIBIOTIC
RESISTANCE
The depth and diversity of antibiotic resistance genes uncovered
by functional metagenomic selections, many of which are asso-
ciated with mobile genetic elements, brings to light the need
for novel strategies to combat antibiotic-resistant pathogens.
Alternative approaches that modulate the host immune response
(e.g., immunomodulatory peptides, vaccination, therapeutic
antibodies) or target the pathogen (e.g., anti-virulence initiatives,
phage therapy, antibiotic potentiators) have been explored with
some success (Planson et al., 2011; Pieren and Tigges, 2012).
For instance, recent studies have suggested engineered bacte-
riophage as an adjuvant to enhance the bactericidal activity of
antibiotics and avoid evolution of resistance to either (Lu and
Collins, 2009; Parracho et al., 2012). In this case, bacteriophage
is engineered to repress non-essential genes (e.g., the SOS system)
not directly targeted by antibiotics, weakening the cell and poten-
tiating antibiotic activity. Other adjuvant compounds that inhibit
intrinsic repair pathways or cell tolerance mechanisms are being
explored (Fischbach, 2011).
Several permeabilizing products capable of disturbing the cell
membrane have been identified, thus allowing antibiotics to pen-
etrate the cells more efficiently. One such product is the low
molecular-weight oligosaccharide nanomedicine OligoG, which
is able to disturb multidrug-resistant bacteria (Khan et al., 2012).
Drug efflux pumps, both specific and multidrug-resistant,
may be inhibited through a variety of strategies. These include
interfering with the expression of a functional transporter at
different stages between transcription and final assembly, inter-
fering with the assembly of channel proteins, designing inhibitors
that compete with the antibiotic for efflux, disrupting the energy
source, and blocking the efflux channel (Pages and Amaral, 2009).
Deletion of genes involved in expression of porins has been
shown to increase antibiotic resistance (Rodrigues et al., 2011).
Therefore, strategies combining overexpression of porins used by
the antibiotic to penetrate the cell with downregulation of efflux
pumps may allow the antibiotic to overcome existing resistance
mechanisms.
CONCLUSION
Functional metagenomic selections are a powerful technique
for high-throughput characterization of the transferable resis-
tome encoded by environmental and human-associated micro-
bial communities, which have the potential to provide human
pathogens with resistance genes through HGT. The advantages
of this technique over traditional culture- and sequence-based
screens are underlined when considering novel resistance mecha-
nisms. Because resistance genes are selected on the basis of func-
tion regardless of sequence, the functional metagenomic selec-
tions reviewed above identified numerous genes with sequences
highly divergent from other members of their class, as well as
novel resistance mechanisms that would not have been recog-
nized as resistance genes based on sequence alone. Conversely,
they confirm antibiotic resistance function in putative drug trans-
porters, which are frequently annotated as such regardless of true
resistance ability, and permit the accurate annotation of resis-
tance genes typically associated with other cellular functions.
They have also led to the discovery of confirmed bifunctional
enzymes, with broad resistance spectrums resulting from the
fusion of two resistance genes. By providing a broader under-
standing of the resistance mechanisms currently in existence,
functional metagenomic selections will aid the production of
new antibiotics less susceptible to existing resistance mecha-
nisms, as well as alternative strategies for combating antibiotic
resistance.
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